United Health Products Reports Zero Revenue and Increased Net Loss in Q2 2026

United Health Products, Inc. (UHP) reported its financial results for the second quarter of 2026, revealing a continued lack of revenue generation, with total revenues remaining at $0 for both the three and six months ended June 30, 2026, and 2025. The company has been focusing its resources on obtaining Premarket Approval (PMA) for its CelluSTAT hemostatic gauze, which has delayed revenue production. The net loss for the second quarter of 2026 was $284,140, a slight improvement from the $315,187 loss reported in the same period last year. For the first half of 2026, the net loss was $599,982, significantly reduced from $1,854,316 in the prior year.

Operating expenses for the second quarter decreased to $166,850 from $268,356 in the same quarter of 2025, primarily due to reduced research and development costs and the termination of certain consulting services. For the six-month period, operating expenses dropped to $432,431 from $1,765,042, largely attributed to a decrease in stock-based compensation and consulting expenses. However, other expenses increased, particularly interest expenses related to outstanding convertible notes, which contributed to the overall net loss.

As of June 30, 2026, UHP's total assets were reported at $247,985, down from $316,698 at the end of 2025. The company's cash and cash equivalents also decreased to $24,495 from $65,249. Current liabilities increased to $4,188,234, compared to $4,051,670 at the end of the previous fiscal year, reflecting higher accounts payable and accrued expenses. The stockholders' deficit widened to $4,442,816 from $3,984,972, indicating ongoing financial challenges.

Strategically, UHP is pursuing FDA approval for its CelluSTAT product, which is designed to control bleeding in surgical and wound care settings. The company has faced regulatory hurdles, including a Warning Letter from the FDA regarding past clinical study compliance. In response, UHP has engaged in corrective actions and is working with an external monitor to ensure adherence to good clinical practices. The company has also entered into financing agreements, including a Securities Purchase Agreement with Alumni Capital, which allows for the potential sale of up to $4 million in common stock to support its operations.

Looking ahead, UHP's management has expressed uncertainty regarding the timing of FDA approvals and the company's ability to continue as a going concern. The company plans to finance its future activities primarily through equity sales and is exploring potential partnerships or mergers to enhance its market position. The ongoing focus remains on resolving regulatory issues and advancing the PMA application for CelluSTAT, which is seen as critical for future revenue generation.